Needham & Company LLC Reaffirms Buy Rating for LivaNova (NASDAQ:LIVN)

LivaNova (NASDAQ:LIVN)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research note issued on Tuesday,Benzinga reports. They presently have a $75.00 price target on the stock. Needham & Company LLC’s target price would indicate a potential upside of 47.84% from the company’s previous close.

Several other equities analysts have also recently commented on the stock. Mizuho decreased their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 target price for the company. Robert W. Baird lifted their price objective on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Finally, StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 23rd. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $69.17.

LivaNova Stock Up 0.4 %

Shares of NASDAQ:LIVN opened at $50.73 on Tuesday. The firm’s 50-day moving average is $49.04 and its two-hundred day moving average is $49.96. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova has a 1 year low of $43.15 and a 1 year high of $64.47. The firm has a market capitalization of $2.75 billion, a PE ratio of 120.79 and a beta of 1.01.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.27% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LivaNova

A number of institutional investors and hedge funds have recently bought and sold shares of LIVN. Point72 Asset Management L.P. increased its position in shares of LivaNova by 62.7% during the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares in the last quarter. Geode Capital Management LLC lifted its stake in LivaNova by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after buying an additional 8,331 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of LivaNova by 16.6% in the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock valued at $49,130,000 after acquiring an additional 133,401 shares during the period. Allspring Global Investments Holdings LLC grew its position in shares of LivaNova by 3.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company’s stock worth $41,889,000 after acquiring an additional 25,277 shares during the last quarter. Finally, Emerald Advisers LLC increased its holdings in shares of LivaNova by 2.1% in the 3rd quarter. Emerald Advisers LLC now owns 695,505 shares of the company’s stock valued at $36,542,000 after acquiring an additional 14,302 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.